Leqvio under the microscope: real-world safety study launched for cholesterol drug
NCT ID NCT06770543
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 1,500 adults with high cholesterol who are prescribed Leqvio (inclisiran) in routine care. The goal is to monitor side effects and measure how well the drug lowers LDL cholesterol. It is a mandatory safety review required by Korean health authorities, not a test of a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGYangsan, Gyeongsangnam-do, 50612, South Korea
-
Novartis Investigative Site
RECRUITINGBusan, 49241, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 04763, South Korea
-
Novartis Investigative Site
RECRUITINGTaegu, 41944, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.